Comparison of the efficacy and safety of Eudragit‐L‐coated mesalazine tablets with ethylcellulose‐coated mesalazine tablets in patients with mild to moderately active ulcerative colitis

Gibson, Peter R.; Fixa, B; Pekárková, Božena; Bátovský, M; Radford‐Smith, Graham; Tibitanzl, J; Gabalec, Libor; Florin, Timothy H.; Greinwald, Roland

doi:10.1111/j.1365-2036.2006.02861.x

Cited by 45 publications

(26 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Riley index was developed in 1991, including 6 histological features assessing acute and chronic inflammation. It was assessed on 82 biopsy samples for interobserver variability in the original publication and in a cohort of 215 Australian patients and was found to be highly reproducible 6 29. It has also been used in relatively few clinical trials 29–31.…”

Section: Discussionmentioning

confidence: 99%

Comparing histological activity indexes in UC

Bressenot

Salleron

Bastien

et al. 2014

Gut

147

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Comparing histological activity indexes in UC

Bressenot

Salleron

Bastien

et al. 2014

Gut

147

View full text Add to dashboard Cite

show abstract

“…Given the equivalence of performance of Eudragit L (Asacol), the coated targeted delivery formulation used in our drug release simulation, and ethyl cellulose-coated formulations used in the calibration and validation of the current model (Gibson et al, 2006), computations can now be made to indirectly validate the predicted luminal compartment drug concentration. With use of the 4-g oncedaily dose, the area under the drug rate versus time curve (Fig.…”

Section: Discussionmentioning

confidence: 99%

SIMDOT-AbMe: Microphysiologically Based Simulation Tool for Quantitative Prediction of Systemic and Local Bioavailability of Targeted Oral Delivery Formulations

Haddish‐Berhane

Farhadi²,

Nyquist³

et al. 2008

Drug Metab Dispos

View full text Add to dashboard Cite

ABSTRACT:The purpose of this study was to develop a physiologically based simulation tool that is able to predict local as well as systemic bioavailability of 5-aminosalicylic acid (5-ASA)-targeted delivery formulations using the existing understanding of the transport and metabolism mechanisms of 5-ASA. The model accounts for active and passive transcellular transport (absorptive and efflux), passive paracellular transport, intestinal biotransformation, and systemic metabolism and clearance. The intestinal physiology was represented by transverse segments for ileum and proximal colon and longitudinal compartments for the microphysiology of the intestinal tissue. The tool, equipped with an optimization routine that enables tuning model parameters, was developed in Matlab and uses a user-friendly graphical interface for data input and output. Physiologic and kinetic model parameters were estimated either from literature monolayer transport studies using nonlinear curve fitting or obtained directly from the literature. 5-ASA clinical pharmacokinetic profiles of a once-daily (one 4-g/day dose) and twicedaily (two 2-g/day doses) dosing regimen were used to partially calibrate and validate the model, respectively. Simulation results showed that drug C max in the gut mucosal layers reached a higher level and was achieved sooner than in the systemic blood level. The computed relative local bioavailability with respect to the systemic bioavailability was 0.063. With use of the model, the relative local bioavailability of different formulations can be established for fast performance verification of new preparations based on measured systemic bioavailability. These types of models play a critical role in designing such preparations and rapidly assessing their effectiveness and will foster efficient experimental designs, saving time and resources.

show abstract

“…Безусловно то, что все имеющиеся на сегодняшний день препараты 5-АСК показали неоспоримое преиму-щество в сравнении с плацебо как в индукции ремиссии, так и в ее удержании в рамках базисной монотерапии, обеспечивая заживление слизистой оболочки толстой кишки, рассматривающееся как основная цель терапии при ЯК [16][17][18][19][20][21][22].…”

Section: препараты месалазина и их точка приложенияunclassified

Mesalazine Place in Therapy of Ulcerative Colitis

Бакулин¹,

Скалинская²,

Сказываева³

2017

Med. sov.

View full text Add to dashboard Cite

Препараты 5-аминосалициловой кислоты (месалазин) используются в качестве терапии первой линии для индукции ремиссии при минимальной активности ЯК и как приоритетные препараты для противорецидивной терапии пациентов с ЯК и включены в российские рекомендации по терапии колита легкой и умеренной активности. Выбор препарата и его формы требует индивидуального подхода, должен основываться на протяженности ЯК, активности воспалительного про-цесса на момент принятия решения о терапии, профиле безопасности препарата, эффективности и переносимости.

show abstract

Comparison of the efficacy and safety of Eudragit‐L‐coated mesalazine tablets with ethylcellulose‐coated mesalazine tablets in patients with mild to moderately active ulcerative colitis

Abstract: SUMMARY BackgroundThere are no comparative studies of coated mesalazine.

Cited by 45 publications

References 25 publications

Comparing histological activity indexes in UC

Comparing histological activity indexes in UC

SIMDOT-AbMe: Microphysiologically Based Simulation Tool for Quantitative Prediction of Systemic and Local Bioavailability of Targeted Oral Delivery Formulations

Mesalazine Place in Therapy of Ulcerative Colitis

Contact Info

Product

Resources

About